Incyte Genomics UBS Global Biopharma Conference 2026
Review the key takeaways and the transcript of this earnings call.
Transcript
Preview the first fifteen paragraphs, organized by speaker.
All right. Good day, everybody. Welcome to UBS Global Biopharma Conference in London. Next company with me here, Incyte. I am really excited to present Pablo Cagnoni, who is the President and Global Head of R&D, excuse me, and Suky Upadhyay, who is EVP and Chief Financial Officer. Thank you guys for joining us. My name is Ashutosh Verma. For those of you who do not know me, I cover small-cap biotech and spec pharma at UBS. I think there is a lot of focus on just the pipeline build-out for Incyte, a lot of programs that you have provided recent updates around. If you can maybe just give some high-level thoughts to start off with, and then we can dive more in specific into the assets.
Certainly, and thank you. Thank you for having us here today. We have two big pillars of the strategy that we are executing against over the next few years. One is to continue to grow the ex-Jakafi core business. That is a key component of the strategy. Drugs that are currently commercialized, like OPZELURA, MONJUVI, NIKTIMVO, ZYNYZ, grow those brands as much as possible in the next few years, including, hopefully early 2027, the launch of povorcitinib as well in that bucket. That, together with the conversion of Jakafi to Jakafi XR, will provide a floor and will continue to support the company going forward through the LOE of Jakafi at the end of 2028. The second pillar of the strategy is executing on the pipeline, as you pointed out. We have a very exciting pipeline. We have a number of drugs already in pivotal trials.
We provided an update recently, and I am sure we will spend time talking about the individual programs. We have our G12D program in phase III. We have latarcibart, our Protein S modulator, in phase III. TGF-beta by PD-1 in phase III as well. Obviously, we have more povo launches coming up as well, and of course, our CALR program in phase III as well. Those programs will start producing pivotal data and launches in the 2028, 2029, and beyond. The goal is to have a fast-growing company with a double-digit CAGR coming out of the LOE after that, driven a bit by the pipeline that I am sure we will discuss in more detail.
Great. That is awesome. So yeah, I guess, talking about the mutant CALR, Pablo, there has been a lot of focus on this first-line MF data that we are going to get at the ASH conference. As much as you say to people that, "Do not focus on the abstract," people definitely look at that, right? Just if you can talk a little bit about what is the data that we saw and what more to expect at the ASH conference, and then I will ask some more specific follow-ups.
Earlier this year at the EHA meeting, we reported, as you know, a group of patients that we call JAK ineligible, right? Those are previously untreated with a JAK inhibitor, but they were ineligible, usually because of anemia, so it is a different population of patients. What you are going to see for the first time at ASH is a group of patients that are JAK eligible with previously untreated MF. It is a group of about 40 patients that we are going to present with a firm and a follow-up at this point, and there are two sets of patients because we randomized them to single agent 989, our CALR antibody, and the combination of 989 with Jakafi.
The reason why we try not to focus on the abstract right now is we have a lot more follow-up and more patients in the presentation, and that is the mature data that we should focus on. One way to start thinking about the data is if you look at the ineligible cohort that we presented at EHA, that is sort of like a floor that you should expect, right? Because those are ineligible patients, and there is no combination Jakafi arm in that group. The ASH data will be true frontline patients. It is really important because it is a piece of data that we need to finalize the design of the frontline MF study that we will initiate in the first half of 2027. So that is why it is a really important data release for us, and why we are so excited about ASH coming up in just a few weeks.
Yeah. The way that, I know in the abstract, it is kind of just like getting early glimpse of the data, but you have combined the JAK ineligible and true naive patients, right? When you start to sort of parse that through, what should we expect, either on the SVR35 or TSS50? Yeah, I think you said that JAK ineligible should be the floor for the efficacy levels, on both the metrics, or?
You should expect that the data in JAK eligible patients to be better than the data in ineligible patients. I am not going to get into how much better it is going to be or could be. We are going to have to wait a couple of weeks. But you should expect that that is the floor where the efficacy of this drug would be. The other important factor in true eligible patients is going to be the impact of 989 on anemia in these patients, which again, you got a glimpse of that in the second-line patients and in the ineligible patients back at EHA.
Now you will see the impact of 989 on anemia improvement in patients with previously untreated MF, and I think that is a really important piece of data that I think should also be reassuring, because 989 is designed to basically normalize hematopoiesis in these patients, to suppress the malignant clone and allow the wild-type clone to re-expand and take over. That is what you will see when we look at the anemia data.
Yeah. Just if I talk about the difference between the monotherapy 989 and the Rux combo, I mean, so far, the data that we have seen, not a big stark difference, I guess. When you think about it, I am sure we will see more data, but when you think about the kind of unity of the combo, where does that fit in the broader picture?
We know what Jakafi does very well. It acts very quickly, it alleviates symptoms very quickly, and it has established a certain rate of SVR35. Although, we know that in CALR-mutated patients, the SVR35 on Jakafi from two different studies, about 20% or 22%. It is not very good at shrinking spleens in CALR-positive patients, and we know that. It is fairly good at improving symptoms in that population, and it does so quickly. The problem with Jakafi is more than 40% of patients develop anemia, and that happens pretty quickly. A lot of patients also develop thrombocytopenia. When we combine it with 989, you should expect maybe improvement on SVR35 over what 989 does alone. But the challenge might be that it blunts a little bit the improvement in anemia that 989 provides, which we think is such an important part of the value proposition for 989.
We will have to see. We will look at all the data with single agent and with combination, and we will, based on that data, make the decision on the design of the phase III trial, which, as I mentioned, we will launch in the first half of 2027. The other important piece of evidence that we need to design that trial is a continued conversation with FDA. As we pointed out, I believe during the earnings call, we think it is time for the FDA to reconsider the approvable endpoints in patients with MF. Historically, since the approval of Jakafi, in fact, the standard endpoints have been SVR35 and TSS50. You know the history. There has been a lot of attempts to beat Jakafi in that setting. They have been unsuccessful. 989 has a fundamentally different mechanism of action, right? It is about, again, eradicating the malignant clone and normalizing hematopoiesis.
We think that needs to be studied with a different set of endpoints. What we are proposing is an endpoint, a composite endpoint that takes into account hemoglobin, platelets, blasts in peripheral blood, and spleen volume. If you meet all four, you succeed. If you fail even one of the four, you don't meet the endpoint. We think that is, A, based on data in the literature, more predictive of survival in the long run in these patients, and we think it defines better the benefit that 989 provides to patients. We have a meeting scheduled in the early part of the first quarter with the FDA to discuss that. There's a special group at the FDA called the Surrogate Endpoints Team. We'll have that conversation, and then we'll provide an update.
If they don't accept that, we'll run a frontline study with SVR35 and TSS50, but we think that might be a better way to go.
Stay tuned. Yeah. I guess, yeah, that'll be an important update to sort of understand the trial design, and when you launch the study, which I believe you're planning for 2027?
FULL TRANSCRIPT
Continue the full translated transcript in StockNow.
Access every statement, the English original, and speaker-by-speaker history with StockNow Pro.
View the full transcript with ProCall participants
3 people spoke on this call — only 1 are shown here.
PARTICIPANT LIST
View participant details in StockNow.
Log in to see executives and analysts, their roles, and complete speaking history.
Log in to view all participantsKeep exploring
